Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 9/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | CEPT1 | Q9Y6K0 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583436 | 0.92 | ADA (0.68) | ADAIKBKBDHODHMTNR1AMTNR1B | |
| SCHEMBL4585499 | 0.91 | ADA (0.55) | ADANPC1RAB9AIKBKB | |
| Hydrochloric Acid SCHEMBL4582809 | 0.90 | ADA (0.54) | ADANPC1RAB9AIKBKB | |
| SCHEMBL4584056 | 0.87 | ADA (0.50) | ADANPC1RAB9AIKBKBDHODH | |
| SCHEMBL4584029 | 0.86 | ADA (0.46) | ADA | |
| SCHEMBL4584306 | 0.85 | ADA (0.50) | ADA | |
| Hydrochloric Acid SCHEMBL4583751 | 0.84 | ADA (0.49) | ADA | |
| SCHEMBL4584630 | 0.82 | ADA (0.46) | ADAIKBKB | |
| Hydrochloric Acid SCHEMBL4582960 | 0.82 | ADA (0.46) | ADA | |
| SCHEMBL4582912 | 0.80 | ADA (0.86) | ADAMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317107-B2 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ASTELLAS PHARMA INC. (JP) | 2008-01-08 | — | — | US | claimed |
| US-20050159462-A1 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ASTELLAS PHARMA INC. (JP) | 2005-07-21 | — | — | US | claimed |
| US-7317107-B2 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ASTELLAS PHARMA INC. (JP) | 2008-01-08 | — | — | US | disclosed |
| US-20050159462-A1 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ASTELLAS PHARMA INC. (JP) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159462-A1 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ADA, AMPD2, AMPD1 | ADA 1/4885NPC1 1630/4885RAB9A 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.